Invention Grant
- Patent Title: Conjugated β-1,3-linked glucans
- Patent Title (中): 共轭β-1,3-连接葡聚糖
-
Application No.: US13928070Application Date: 2013-06-26
-
Publication No.: US09439955B2Publication Date: 2016-09-13
- Inventor: Francesco Berti , Paolo Costantino , Maria Rosaria Romano
- Applicant: Novartis AG
- Applicant Address: BE Rixensart
- Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
- Current Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
- Current Assignee Address: BE Rixensart
- Agency: Robins Law Group
- Agent Robert L. Robins
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K47/48 ; A61K39/385 ; A61K31/716 ; A61P37/02 ; C08B37/00 ; C07K14/195 ; A61K9/00 ; A61K9/02 ; A61K9/107

Abstract:
Glucans having exclusively or mainly β-1,3 linkages are used as immunogens. These comprise β-1,3-linked glucose residues. Optionally, they may include β-1,6-linked glucose residues, provided that the ratio of β-1,3-linked residues to β-1,6-linked residues is at least 8:1 and/or there are one or more sequences of at least five adjacent non-terminal residues linked to other residues only by β-1,3 linkages. The glucans will usually be used in conjugated form. A preferred glucan source is curdlan, which may be hydrolyzed to a suitable form prior to conjugation.
Public/Granted literature
- US20130315960A1 CONJUGATED BETA-1,3-LINKED GLUCANS Public/Granted day:2013-11-28
Information query